Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 6/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21567203 | 1.00 | CHRNB4 (0.38) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15038199 | 0.98 | CYP1A2 (0.39) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19931584 | 0.93 | — | — | |
| SCHEMBL18270966 | 0.93 | — | — | |
| SCHEMBL14930351 | 0.93 | — | — | |
| SCHEMBL18270874 | 0.82 | — | — | |
| SCHEMBL18270877 | 0.82 | — | — | |
| SCHEMBL17735692 | 0.78 | CHRNB4 (0.43) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7600904 | 0.78 | CHRNB4 (0.43) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13416621 | 0.78 | CHRNB4 (0.43) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193714-B2 | Fluorinated estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150005286-A1 | FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. | 2015-01-01 | — | — | US | disclosed |
| WO-2013090836-A1 | FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005286-A1 | FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GPER1, ESR2, ESRRG | CHRNB4 1139/4885CHRNA3 792/4885SLC6A2 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.